WaveMan
WaveMan · Company
PCSA · Processa Pharmaceuticals, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

PCSA Processa Pharmaceuticals (PCSA) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001533743
Quote by TradingView
Cluster · 6 insidersC-suite buying · 6
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
8
13F, latest reported quarter
Conversions, 180 days
5
Codes C/M, not in net · no price filed

What the filings say about PCSA

Insiders, 180 days
+$135.4K net bought
6 buyers

Processa Pharmaceuticals insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Processa Pharmaceuticals, Inc. insiders bought a net $135.4K of stock across 68 Form 4 purchases and sales, with 6 insiders buying. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
Ng George K
Chief Executive Officer
BUY
2026-07-01 SEC
3,057
$5.9K
-16.2%
Context
  • 9 earlier Form 4 trades (code P or S) here by this insider (9 buys), the last on Jun 15, 2026.
  • -22.4% median (-25.3% mean) 90-day return after 8 previous buys.
  • The trade is 19.7% of the 15,492 shares held after it.
  • 4 other insiders bought within 30 days.
  • 8 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Ng George K bought about $5.9K of PCSA on Jul 1, 2026; 4 other insiders bought within 30 days and 8 funds added in the latest 13F quarter.
Guy Wendy
Chief Administrative Officer
BUY
2026-07-01 SECtraded 2026-06-30
2,436
$4.7K
-16.2%
Context
  • 6 earlier Form 4 trades (code P or S) here by this insider (6 buys), the last on Jun 15, 2026.
  • -20.1% median (-19.8% mean) 90-day return after 6 previous buys.
  • The trade is 16.9% of the 14,394 shares held after it.
  • 4 other insiders bought within 30 days.
  • 8 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Administrative Officer Guy Wendy bought about $4.7K of PCSA on Jun 30, 2026; 4 other insiders bought within 30 days and 8 funds added in the latest 13F quarter.
Lin Patrick
Chief Business - Strategy Off
BUY
2026-07-01 SECtraded 2026-06-30
2,106
$4.1K
-16.2%
Context
  • 16 earlier Form 4 trades (code P or S) here by this insider (16 buys), the last on Jun 15, 2026.
  • -14.9% median (-11.6% mean) 90-day return after 15 previous buys.
  • The trade is 16.1% of the 13,113 shares held after it.
  • 4 other insiders bought within 30 days.
  • 8 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Business - Strategy Off Lin Patrick bought about $4.1K of PCSA on Jun 30, 2026; 4 other insiders bought within 30 days and 8 funds added in the latest 13F quarter.
Young David
Pres. Research & Development
BUY
2026-07-01 SECtraded 2026-06-30
2,531
$4.9K
-16.2%
Context
  • 14 earlier Form 4 trades (code P or S) here by this insider (14 buys), the last on Jun 15, 2026.
  • -15.2% median (-14.8% mean) 90-day return after 14 previous buys.
  • The trade is 11.6% of the 21,729 shares held after it.
  • 4 other insiders bought within 30 days.
  • 8 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Pres. Research & Development Young David bought about $4.9K of PCSA on Jun 30, 2026; 4 other insiders bought within 30 days and 8 funds added in the latest 13F quarter.
SKIBSTED RUSSELL
Chief Financial Officer
BUY
2026-07-01 SECtraded 2026-06-30
3,277
$6.3K
-16.2%
Context
  • 6 earlier Form 4 trades (code P or S) here by this insider (6 buys), the last on Jun 15, 2026.
  • -20.1% median (-19.8% mean) 90-day return after 6 previous buys.
  • The trade is 19.6% of the 16,689 shares held after it.
  • 4 other insiders bought within 30 days.
  • 8 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer SKIBSTED RUSSELL bought about $6.3K of PCSA on Jun 30, 2026, the largest insider purchase at the company since 2025; 4 other insiders bought within 30 days and 8 funds added in the latest 13F quarter.
68 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 63 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$135.4K over 180 days
more than 77% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
8 funds bought in last quarter
below 89% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
0.1% of the float short (float per yahoo 2026-10-26) · 1.0 days to cover · settled 2026-09-30
below 87% of Pharma & Biotech
The situation: each line is one rule over one dataset
6 insiders independently bought a net $135.4K while the stock fell 39% over six months, with no planned sales queued.
1 clinical trial was terminated, suspended or withdrawn in the last 90 days.
What changed in the last 30 days
Oct 27Insider buying stopped: no purchases in 90 days after 20 in the prior 90
Why it matters
The absence is the signal: 20 purchases in one 90-day window and none in the next is a change of behaviour, not a filing.

Watch PCSA

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-74.0%12M
-81%-40%-0%+40%2025-102025-122026-022026-042026-062026-082026-10 2026-06-30 · SKIBSTED RUSSELL bought $6.3K2026-03-31 · SKIBSTED RUSSELL bought $5.9K2026-07-01 · Ng George K bought $5.9K2026-04-15 · SKIBSTED RUSSELL bought $5.9K2026-05-15 · SKIBSTED RUSSELL bought $5.9K2026-06-15 · SKIBSTED RUSSELL bought $5.9K2026-04-30 · SKIBSTED RUSSELL bought $5.9K2026-05-29 · SKIBSTED RUSSELL bought $5.9K2026-03-31 · Baluch Khoso bought $5.8K2026-04-15 · Ng George K bought $5.5K2026-04-15 · Ng George K bought $5.5K2026-05-15 · Ng George K bought $5.5K2026-06-15 · Ng George K bought $5.5K2026-05-29 · Ng George K bought $5.5K2026-04-30 · Ng George K bought $5.5K2026-03-31 · Ng George K bought $5.4K2026-03-31 · Bigora Sian bought $5.4K2026-04-15 · Bigora Sian bought $5.3K2026-04-30 · Bigora Sian bought $5.3K2026-04-30 · Bigora Sian bought $5.3K2026-03-31 · Pannu Geraldine bought $5.3K2026-06-30 · Young David bought $4.9K2026-03-31 · Guy Wendy bought $4.7K2026-04-30 · Guy Wendy bought $4.7K2026-06-15 · Guy Wendy bought $4.7K2026-04-15 · Guy Wendy bought $4.7K2026-05-15 · Guy Wendy bought $4.7K2026-06-30 · Guy Wendy bought $4.7K2026-05-29 · Guy Wendy bought $4.7K2026-03-31 · Young David bought $4.6K2026-05-29 · Young David bought $4.6K2026-04-30 · Young David bought $4.6K2026-06-15 · Young David bought $4.6K2026-04-15 · Young David bought $4.6K2026-05-15 · Young David bought $4.6K2026-03-31 · Lin Patrick bought $4.1K2026-04-15 · Lin Patrick bought $4.1K2026-05-15 · Lin Patrick bought $4.1K2026-05-29 · Lin Patrick bought $4.1K2026-06-15 · Lin Patrick bought $4.1K2026-04-30 · Lin Patrick bought $4.1K2026-06-30 · Lin Patrick bought $4.1K
Insider buy
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns PCSA: institutional holders (13F)

13F holdings, latest reported quarter
Stonepine Capital Management, LLC
110,000 sh
$211.2K
Connective Capital Management, LLC
85,274 sh
$163.7K
GEODE CAPITAL MANAGEMENT, LLC
22,090 sh
$42.4K
CITADEL ADVISORS LLC
21,306 sh
$40.9K
StoneX Group Inc.
11,437 sh
$29.6K

Congress trades in PCSA

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

PCSA planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

PCSA mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Extended Market Index Fund
$36.4K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$24.4K position · as of 2026-06-30
0.0%
Fidelity Series Total Market Index Fund
$5.3K position · as of 2026-05-31
0.0%
Fidelity Total Market Index Fund
$2.5K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
7 registered trials, 0 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
1
Phase 1
0 active
4
Phase 2
0 active
2
Multi-phase
0 active
What changed recently
A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Bre
2026-10-07 · Recruiting → Terminated · Business Reason
Phase 2
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
6 insiders reported buying shares.
The record shows a net $135.4K bought by insiders over 180 days, 8 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

PCSA financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$0
four quarters, 2022-10-01 to 2023-09-30
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Free cash flow, TTM
n/a
capex not filed for the four quarters
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Cash flow to debt
-52.05x
TTM operating cash flow over current debt only, 2018-12-31 (91 months older than the period end)
Return on equity
-464.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-262.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-444.2%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$5.1M
market value at close 2026-10-23 on 2026-08-07 shares, plus current debt only, 2018-12-31 (91 months older than the period end), minus cash 2026-06-30
FCF yield
n/a
capex not filed for the four quarters
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenuen/an/an/a$0
Operating income-$14.0M-$12.1M-$11.5M-$27.5M
Net income-$13.6M-$11.8M-$11.1M-$27.4M
EPS (diluted)-10.36-96.78-8.48-34.05
Operating cash flow-$11.4M-$11.2M-$8.1M-$9.6M
Cash$5.5M$1.2M$4.7M$6.5M
SEC XBRL, fiscal years, as known on 2026-10-27

PCSA Stock Sonar score 5/7 axes

Find similar shapesCompare

PCSA ranks highest on insider conviction (87th percentile) and risk and compliance (54th), and lowest on profitability (6th), among Pharma & Biotech peers.

ProfitHealthInsidersInstitutionsRisk
Profitability
6
Inputs
  • Return on equity-464.2% · 8 pct, sector of 545
  • Return on assets-262.2% · 8 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-444.2% · 3 pct, sector of 576
Financial health
11
Inputs
  • Debt to equityequity is zero or negative, the ratio has no meaning
  • Cash flow to debt-52.05x · 11 pct, sector of 371
Insider conviction
87
Inputs
  • Net Form 4 buying (codes P and S), 180d$135K · 77 pct, sector of 428
  • Insider buyers, 180d6 · 97 pct, sector of 437
Institutional and government
11
Inputs
  • Funds adding, latest quarter8 · 11 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
54
Inputs
  • Short interest, % of float+0.1% · 92 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+20.3% · 16 pct, sector of 511
2 not measured: Growth, US patents
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

PCSA filings, in plain words

Are Processa Pharmaceuticals insiders buying or selling PCSA?

In the 180 days to 2026-10-27, Processa Pharmaceuticals insiders were net buyers, a net $135.4K across purchases and sales reported on Form 4, by 6 buyers.

Read the full summary

In the 180 days to 2026-10-27, Processa Pharmaceuticals insiders were net buyers of PCSA, a net $135.4K across purchases and sales reported on Form 4 by 6 buyers. 6 insiders reported purchases in that window. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies